Loading...
•
Mar 31, 2021
Heron Therapeutics Q1 2021 Earnings Report
Heron Therapeutics reported a net loss for the first quarter of 2021, with oncology care franchise net product sales declining compared to the same period in 2020, while awaiting FDA decision on HTX-011.
Key Takeaways
Heron Therapeutics reported a net loss of $52.6 million for the first quarter of 2021. Net product sales were $20.0 million, a decrease from $25.4 million in the same period of 2020. The company is awaiting the FDA's decision on its New Drug Application for HTX-011.
Oncology care franchise net product sales were $20.0 million, down from $25.4 million in Q1 2020.
Net loss for the quarter was $52.6 million, or $0.58 per share, compared to a net loss of $51.6 million, or $0.57 per share, for the same period in 2020.
The FDA is reviewing the New Drug Application resubmission for HTX-011, with a PDUFA goal date of May 12, 2021.
Heron expects full-year 2021 net product sales for the oncology care franchise of $130 million to $145 million.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.com Forward Guidance
Heron expects full-year 2021 net product sales for the oncology care franchise of $130 million to $145 million.